ArticleFrontiers in medicine2025
Case Report: Anaphylactic shock induced by cefoperazone sodium and sulbactam sodium for injection.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance and toxicological studies on safety signals associated with the combined use of propofol and midazolam.BMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Cefoperazone-sulbactam is a widely used antibiotic in clinical practice, and anaphylactic shock is a severe adverse drug reaction. Previous literature has rarely reported cases of anaphylactic shock induced by cefoperazone-sulbactam. Patient concerns: A 38-year-old male patient who underwent surgery for cerebral hemorrhage developed fever, with considerations of pulmonary and urinary tract infections. Following the administration of injectable cefoperazone-sulbactam, he experienced anaphylactic shock. Diagnosis: Anaphylactic shock was suspected to be caused by injectable cefoperazone-sulbactam. Interventions: The patient was administered a subcutaneous injection of 1 mg epinephrine, followed by continuous infusion of 10 mg norepinephrine in 45 mL of 5% glucose solution via a pump. Additionally, assisted ventilation with a respirator and fluid resuscitation were provided. Outcome: The patient was discharged with improved symptoms. Lessons: To prevent serious adverse reactions, it is essential to strictly adhere to indications and contraindications to avoid misuse and minimize the occurrence of adverse effects. Prior to medication administration, a thorough inquiry into the patient's drug allergy history and family history should be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.